Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Spectral Medical Inc T.EDT

Alternate Symbol(s):  EDTXF

Spectral Medical Inc. is a Canada-based late-stage theragnostic company advancing therapeutic options for sepsis and septic shock. The Company develops and commercializes a treatment for septic shock utilizing its Endotoxin Activity Assay (EAA) diagnostic and the Toraymyxin therapeutic (PMX). PMX is a therapeutic hemoperfusion device that removes endotoxin, which can cause sepsis, from the bloodstream and is guided by the Company’s EAA. PMX is approved for therapeutic use in Japan and Europe and has been used safely and effectively on more than 340,000 patients to date. It has pioneered the development of biochemical markers for the clinical syndrome known as septic shock. It is continuing its legacy business of manufacturing and selling certain proprietary reagents. It develops, produces and markets recombinant proteins, antibodies and calibrators. These materials are sold for use in research and development, as well as in products manufactured by other diagnostic companies.


TSX:EDT - Post by User

Post by Stocktreeon Feb 25, 2024 7:49pm
150 Views
Post# 35898228

So funny to read Merman being disappointed at investors

So funny to read Merman being disappointed at investors

who are disappointed in Spectral.

He has been doing that for years, even before the 2016 debacle.
Predicting incredible gains, then blaming the FDA for not moving fast enough, or greed and the blind market for the lack of return on investment.

Then, back to his old shtick, predicting an explosion in the SP while taking out reality out of the equation. "Yes," he says, "Spectral has screwed you, again, boohoo, too bad for you, but that won't happen in the future, believe me, because greed, the FDA, back door dealings and the lack of interest of the market will somehow no longer be a factor one day.

One of this professional poster's favorite lines recently is to ask when will Paradigm review their TP. Yep, as others have pointed out, the target was 4$ a few years ago, and short term at that, but that was when Seto worked at Paradigm. He was subsequently hired by Spectral...

Mm and his friend,  TierTopTom, another long-time senior professional Stockhouse plant, who change his identity several times after having been kicked out from the forum, argued the $4 target was too low, which showed  Paradigm and Spectral were in bed together and they needed the sp to remain low (meaning, according to them, that the investment firm was unreliable anyway).

However, Seto went on to head Spectral and now that the "100% certain" Big Event is much closer, the target is just $1.60???? Again, Mm had been pointing in the wrong direction, even if he was probably not wrong in highlighting, but in an upside down way, that the relationship between Paradigm and Spectral at one point might be qualified as a big conflict of interest. But that won't prevent MM from quoting Paradigm's TP as a convincing in his "analyzes", will it?

It's a wonder why Mm's professional Stockhouse services are even needed, though. Canadian regulators don't even have the teeth or the will to impose a healthy market playing field, and Spectral and analysts can easil go back on their words, hide material information, radically change their expectations and/or mishandle investors money without consequences.

Conclusion, even if the PMX trial is a success, the history of this company has showed repeatedly that such a positive ending will not necessarily translate into a capital gain for unsuspecting retail investors.

<< Previous
Bullboard Posts
Next >>